Claims for Patent: 6,130,041

Summary for Patent: 6,130,041

Title:	Human intronic and polymorphic SR-BI nucleic acids and uses therefor
Abstract:	The present invention is based at least in part on the discovery of the genomic structure of the human SR-BI gene and on the identification of polymorphic regions within the gene. Accordingly, the invention provides nucleic acids having a nucleotide sequence of an allelic variant of an SR-BI gene and nucleic acids having an SR-BI intronic sequence. The invention also provides methods for identifying specific alleles of polymorphic regions of an SR-BI gene, methods for determining whether a subject has or is at risk of developing a disease which is associated with a specific allele of a polymorphic region of an SR-BI gene, and kits for performing such methods.
Inventor(s):	Acton; Susan Laurene (Lexington, MA)
Assignee:	Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	09/032,894
Patent Claims:	1. An isolated nucleic acid, comprising an allelic variant of a polymorphic region of an SR-BI gene selected from the group of polymorphic regions consisting of nucleotide 146 of exon 1, nucleotide 119 of exon 3, and nucleotide -41 of intron 10, which allelic variant differs from the allelic variant set forth in SEQ ID NO: 1 or 3. 2. An isolated nucleic acid of claim 1, further comprising at least a portion of an exon. 3. An isolated nucleic acid of claim 1, comprising from about 15 to about 30 nucleotides. 4. An isolated nucleic acid of claim 1, comprising at least about 31 nucleotides. 5. An isolated nucleic acid of claim 3, comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 95-97. 6. An isolated nucleic acid of claim 1, which is single stranded. 7. An isolated nucleic acid of claim 1, which further comprises a label. 8. An isolated intronic nucleic acid of a genomic DNA comprising an SR-BI gene, wherein the intronic nucleic acid sequence comprises SEQ ID NO: 97. 9. A kit for amplifying and/or for determining the molecular structure of at least a portion of an SR-BI gene, comprising a probe or primer which hybridizes to an SR-BI polymorphic region of any of SEQ ID NO: 88 and 95-97, or complement thereof, and instructions for use. 10. A kit of claim 9, wherein the probe or primer hybridizes to an SR-BI intronic sequence having SEQ ID NO: 88. 11. A kit of claim 9, wherein the probe or primer hybridizes to a nucleic acid comprising an intron/exon border of an SR-BI gene. 12. A kit of claim 9, further comprising a second probe or primer. 13. A kit of claim 9, wherein the probe or primer has a nucleotide sequence from about 15 to about 30 nucleotides. 14. A kit for amplifying and/or for determining the molecular structure of at least a portion of an SR-BI gene, comprising two primers selected from the group consisting of the nucleotide sequences set forth in SEQ ID Nos. 41-64, SEQ ID Nos. 83-84, and SEQ ID Nos. 89-94 and wherein at least one primer is selected from the group consisting of SEQ ID Nos: 89, 90, 93 and 94. 15. A kit of claim 9, wherein the probe or primer is a single stranded nucleic acid. 16. A kit of claim 9, wherein the probe or primer is labeled. 17. A method for determining the identity of an allelic variant of a polymorphic region of an SR-BI gene in a nucleic acid obtained from a subject, comprising contacting a sample nucleic acid comprising an SR-BI gene with a probe or primer which hybridizes to a polymorphic region of an allelic variant of an SR-BI gene consisting of nucleotide 146 of exon 1, nucleotide 119 of exon 3 or nucleotide -41 of intron 10 to thereby determine the identity of the allelic variant. 18. A method of claim 17, wherein the probe or primer hybridizes to an SR-BI intron. 19. A method of claim 17, wherein the probe or primer hybridizes to an allelic variant of a polymorphic region, and wherein the allelic variant differs from the allelic variant set forth in SEQ ID NO: 1 or 3. 20. A method of claim 17, wherein determining the identity of the allelic variant comprises determining the identity of at least one nucleotide of the polymorphic region. 21. A method of claim 17, wherein determining the identity of the allelic variant consists of determining the nucleotide content of the polymorphic region. 22. A method of claim 21, wherein determining the nucleotide content comprises sequencing the nucleotide sequence. 23. A method of claim 17, wherein determining the identity of the allelic variant comprises performing a restriction enzyme site analysis. 24. A method of claim 17, wherein determining the identity of the allelic variant is carried out by single-stranded conformation polymorphism. 25. A method of claim 17, wherein determining the identity of the allelic variant is carried out by allele specific hybridization. 26. A method of claim 17, wherein determining the identity of the allelic variant is carried out by primer specific extension. 27. A method of claim 17, wherein determining the identity of the allelic variant is carried out by an oligonucleotide ligation assay. 28. A method of claim 17, wherein the SR-BI gene is a human SR-BI gene. 29. A method of claim 17, wherein the probe or primer has a nucleotide sequence from about 15 to about 30 nucleotides. 30. A method of claim 29, wherein the probe or primer comprises a nucleotide sequence set forth in any one of SEQ ID Nos. 95, 96, or 97, or the complement thereof. 31. A method of claim 17, wherein the probe or primer is labeled. 32. A method of claim 17, wherein the probe or primer is capable of hybridizing to an intron/exon border of an SR-BI gene. 33. A method of claim 17 for determining whether a subject has, or is at risk of developing, a disease or condition associated with a specific allelic variant of a polymorphic region in the human SR-BI gene, further comprising determining whether the SR-BI gene of the subject comprises an allelic variant that is associated with a disease or condition. 34. A method of claim 33, wherein the disease or condition is an abnormal lipid metabolism, inappropriate lipid levels, a cardiovascular disease, atherosclerosis, gallstone formation or an abnormal body mass index. 35. A method of claim 33, for use in selecting the appropriate drug to administer to a subject to treat a disease which is associated with a specific allele of an SR-BI gene, further comprising determining whether the specific allele is present in a nucleic acid sample of the individual and selecting the appropriate drug if the specific allele is present. 36. A method of claim 35, wherein the disease or condition is abnormal lipid metabolism, inappropriate lipid levels, a cardiovascular disease, atherosclerosis, gallstone formation, or an abnormal body mass index. 37. An isolated nucleic acid of claim 1, wherein the allelic variant comprises a nucleotide sequence set forth in SEQ ID NO: 95. 38. An isolated nucleic acid of claim 1, wherein the allelic variant comprises a nucleotide sequence set forth in SEQ ID NO: 96. 39. An isolated nucleic acid of claim 1, wherein the allelic variant comprises a nucleotide sequence set forth in SEQ ID NO: 97. 40. A kit of claim 9, wherein the allelic variant of a polymorphic region has a nucleotide sequence set forth in SEQ ID NO: 95. 41. A kit of claim 9, wherein the allelic variant of a polymorphic region has a nucleotide sequence set forth in SEQ ID NO: 96. 42. A kit of claim 9, wherein the allelic variant of a polymorphic region has a nucleotide sequence set forth in SEQ ID NO: 97.

Details for Patent 6,130,041

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-07-10
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-07-10
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-07-10